MD - Pediatrix Medical Group reports mixed Q4 earnings; initiates FY23 outlook
- Pediatrix Medical Group press release ( NYSE: MD ): Q4 Non-GAAP EPS of $0.47 misses by $0.02 .
- Revenue of $514M (+3.0% Y/Y) beats by $12.03M .
- Adjusted EBITDA of $66M.
- On a preliminary basis, Pediatrix anticipates that its 2023 Adjusted EBITDA, as defined above, will be in a range of $235 million to $245 million. This outlook does not reflect any additional funds from the provider relief fund established by the CARES Act, which favorably impacted Adjusted EBITDA by approximately $6.7 million for the year ended December 31, 2022.
For further details see:
Pediatrix Medical Group reports mixed Q4 earnings; initiates FY23 outlook